Insider Selling: Hinge Health (NYSE:HNGE) Director Sells $57,100.00 in Stock

Hinge Health Inc. (NYSE:HNGE) Director Kristina Leslie sold 1,250 shares of the business’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $45.68, for a total transaction of $57,100.00. Following the transaction, the director directly owned 27,750 shares in the company, valued at approximately $1,267,620. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Hinge Health Stock Up 3.8%

HNGE opened at $50.12 on Thursday. Hinge Health Inc. has a twelve month low of $33.42 and a twelve month high of $62.18. The company’s fifty day moving average price is $49.13.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.18. The firm had revenue of $154.21 million during the quarter, compared to analysts’ expectations of $142.44 million. Hinge Health’s quarterly revenue was up 53.3% on a year-over-year basis. Hinge Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Hinge Health announced that its Board of Directors has authorized a share repurchase plan on Wednesday, November 12th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to reacquire up to 7.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Institutional Investors Weigh In On Hinge Health

Institutional investors have recently modified their holdings of the business. Lisanti Capital Growth LLC acquired a new position in Hinge Health during the 2nd quarter valued at about $3,089,000. Strategic Blueprint LLC bought a new stake in shares of Hinge Health during the second quarter valued at approximately $346,000. Ensign Peak Advisors Inc acquired a new position in shares of Hinge Health during the second quarter worth approximately $16,172,000. FNY Investment Advisers LLC acquired a new position in shares of Hinge Health during the second quarter worth approximately $310,000. Finally, Foresite Capital Management VI LLC bought a new position in Hinge Health in the 2nd quarter worth approximately $6,986,000.

Analysts Set New Price Targets

Several research firms have issued reports on HNGE. Barclays lifted their price objective on Hinge Health from $62.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Evercore ISI upped their price target on shares of Hinge Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Canaccord Genuity Group increased their price objective on shares of Hinge Health from $61.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Wall Street Zen raised shares of Hinge Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Morgan Stanley upped their target price on shares of Hinge Health from $57.00 to $67.00 and gave the company an “overweight” rating in a research note on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Hinge Health has a consensus rating of “Moderate Buy” and a consensus target price of $59.93.

About Hinge Health

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.